Pfc Pharma Focus India Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.43 M
- Company Age 16 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -29.99%
- Profit Growth -64.86%
- Ebitda -68.46%
- Net Worth 17.81%
- Total Assets 15.32%
About Pfc Pharma Focus India
Pfc Pharma Focus India Private Limited (PPFIPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 June 2008 and has a history of 16 years and seven months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.43 M, as per Ministry of Corporate Affairs (MCA) records.
Saurendra Das, Joseph Amalraj, and Kavitha Joseph serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232DL2008PTC179947
-
Company No.
179947
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Jun 2008
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Pfc Pharma Focus India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kavitha Joseph
|
Director | 12-Feb-2021 | Current |
|
Saurendra Das
|
Additional Director | 15-Oct-2024 | Current |
|
Joseph Amalraj
|
Director | 25-Jul-2022 | Current |
Financial Performance of Pfc Pharma Focus India.
Pfc Pharma Focus India Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 29.99% decrease. The company also saw a substantial fall in profitability, with a 64.86% decrease in profit. The company's net worth Soared by an impressive increase of 17.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pfc Pharma Focus India?
Unlock access to Pfc Pharma Focus India's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Carehomemed Private LimitedJoseph Amalraj is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pfc Pharma Focus India?
Unlock and access historical data on people associated with Pfc Pharma Focus India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pfc Pharma Focus India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pfc Pharma Focus India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
